Rebecca Shoemaker
Overview
Explore the profile of Rebecca Shoemaker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hansen S, Piatak M, Ventura A, Hughes C, Gilbride R, Ford J, et al.
Nature
. 2017 Jun;
547(7661):123-124.
PMID: 28636599
This corrects the article DOI: 10.1038/nature12519.
12.
Jensen K, Dela Pena-Ponce M, Piatak Jr M, Shoemaker R, Oswald K, Jacobs Jr W, et al.
Clin Vaccine Immunol
. 2016 Sep;
24(1).
PMID: 27655885
Our goal is to develop a pediatric combination vaccine to protect the vulnerable infant population against human immunodeficiency virus type 1 (HIV-1) and tuberculosis (TB) infections. The vaccine consists of...
13.
Del Prete G, Oswald K, Lara A, Shoemaker R, Smedley J, MacAllister R, et al.
Antimicrob Agents Chemother
. 2015 Dec;
60(3):1560-72.
PMID: 26711758
Replication-competent human immunodeficiency virus (HIV) persists in infected people despite suppressive combination antiretroviral therapy (cART), and it represents a major obstacle to HIV functional cure or eradication. We have developed...
14.
Fukazawa Y, Lum R, Okoye A, Park H, Matsuda K, Bae J, et al.
Nat Med
. 2015 Jan;
21(2):132-9.
PMID: 25599132
Chronic-phase HIV and simian immunodeficiency virus (SIV) replication is reduced by as much as 10,000-fold in elite controllers (ECs) compared with typical progressors (TPs), but sufficient viral replication persists in...
15.
Del Prete G, Shoemaker R, Oswald K, Lara A, Trubey C, Fast R, et al.
Antimicrob Agents Chemother
. 2014 Sep;
58(11):6790-806.
PMID: 25182644
Nonhuman primate models are needed for evaluations of proposed strategies targeting residual virus that persists in HIV-1-infected individuals receiving suppressive combination antiretroviral therapy (cART). However, relevant nonhuman primate (NHP) models...
16.
Hansen S, Piatak Jr M, Ventura A, Hughes C, Gilbride R, Ford J, et al.
Nature
. 2013 Sep;
502(7469):100-4.
PMID: 24025770
Established infections with the human and simian immunodeficiency viruses (HIV and SIV, respectively) are thought to be permanent with even the most effective immune responses and antiretroviral therapies only able...
17.
Fukazawa Y, Park H, Cameron M, Lefebvre F, Lum R, Coombes N, et al.
Nat Med
. 2012 Sep;
18(11):1673-81.
PMID: 22961108
Live attenuated simian immunodeficiency virus (SIV) vaccines (LAVs) remain the most efficacious of all vaccines in nonhuman primate models of HIV and AIDS, yet the basis of their robust protection...
18.
Hansen S, Ford J, Lewis M, Ventura A, Hughes C, Coyne-Johnson L, et al.
Nature
. 2011 May;
473(7348):523-7.
PMID: 21562493
The acquired immunodeficiency syndrome (AIDS)-causing lentiviruses human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) effectively evade host immunity and, once established, infections with these viruses are only rarely controlled...